Literature DB >> 22165685

Bye-bye chiro-inositol - myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction.

M Galletta1, S Grasso, A Vaiarelli, Scott J Roseff.   

Abstract

Polycystic ovary syndrome (PCOS) is a multifactorial syndrome affecting 10% of women in reproductive age. Insulin sensitizer agents are the best therapeutic option for PCOS patients; among which there is Inositol. Inositol is a polyalcohol existing as nine different stereoisomers, two of which have been shown to be insulin mediators: myo-inositol (MI) and D-chiro-inositol (DCI). So far only MI have been show to be present in the follicular fluid and in a direct comparison between MI and DCI only MI was able to improve oocyte and embryo quality. Therefore, Could we say "bye-bye D-chiro-Inositol" in the practice of clinical gynecology and reproductive medicine?

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22165685

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

Review 1.  The "Other" Inositols and Their Phosphates: Synthesis, Biology, and Medicine (with Recent Advances in myo-Inositol Chemistry).

Authors:  Mark P Thomas; Stephen J Mills; Barry V L Potter
Journal:  Angew Chem Int Ed Engl       Date:  2015-12-22       Impact factor: 15.336

2.  The inositols and polycystic ovary syndrome.

Authors:  Bharti Kalra; Sanjay Kalra; J B Sharma
Journal:  Indian J Endocrinol Metab       Date:  2016 Sep-Oct

Review 3.  Debates Regarding Lean Patients with Polycystic Ovary Syndrome: A Narrative Review.

Authors:  Manu Goyal; Ayman S Dawood
Journal:  J Hum Reprod Sci       Date:  2017 Jul-Sep

Review 4.  Health-Promoting Properties of Selected Cyclitols for Metabolic Syndrome and Diabetes.

Authors:  Tomasz Antonowski; Adam Osowski; Lesław Lahuta; Ryszard Górecki; Andrzej Rynkiewicz; Joanna Wojtkiewicz
Journal:  Nutrients       Date:  2019-09-30       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.